Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 10
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
4/1/1995
1.
Phase II Study of Pyrazine Diazohydroxide Given Daily for 5 Days for Metastatic Renal Cell Cancer (Summary Last Modified 04/95)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
over 18
NCI
UCCRC-7483
NCI-T94-0145H, T94-0145
Last Modified:
2/1/1995
2.
Phase II Study of Pyrazine Diazohydroxide for Advanced Colon or Rectal Cancer (Summary Last Modified 02/95)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
NCI
UCCRC-7500
NCI-T94-0146H, T94-0146
Last Modified:
1/1/1997
3.
Phase II Study of Pyrazine Diazohydroxide in Advanced Nonsmall Cell Lung Cancer (Summary Last Modified 01/97)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
NCI
CCCWFU-62194
NCI-T94-0188D, T94-0188
Last Modified:
1/1/2000
4.
Phase II Study of Pyrazine Diazohydroxide for Advanced Nonsmall Cell Lung Cancer (Summary Last Modified 01/2000)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
over 18
NCI
AECM-1199412478
NCI-T94-0190O, T94-0190
Last Modified:
4/1/1998
5.
Phase II Study of Pyrazine Diazohydroxide in Hormone-Refractory Prostate Cancer (Summary Last Modified 04/98)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
NCI
UCDCC-104
NCI-T95-0005D, T95-0005
Last Modified:
12/1/1997
6.
Phase II Study of Pyrazine Diazohydroxide in Chemotherapy-Naive Patients with Disseminated Malignant Melanoma (Summary Last Modified 12/97)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
no age specified
NCI
SWOG-9505
SWOG-9505
Last Modified:
9/1/1999
7.
Phase I Study of Pyrazine Diazohydroxide Administered on a 5-Day Bolus Schedule for Refractory Acute Leukemias and Blastic Phase Chronic Myelogenous Leukemia (Summary Last Modified 09/1999)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
over 15
NCI
MDA-DM-94109
NCI-T94-0157D, T94-0157
Last Modified:
6/1/1992
8.
Phase I Study of Pyrazine Diazohydroxide Given by Intravenous Infusion Every Three Weeks in Patients with Advanced Malignancies (Summary Last Modified 06/92)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 and over
NCI
MAYO-890101
NCI-T89-0053C, T89-0053
Last Modified:
11/1/1990
9.
Phase I Clinical and Pharmacokinetic Investigation of Pyrazine Diazohydroxide in Patients with Refractory Solid Malignancies (Summary Last Modified 11/90)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
over 18
NCI
OSU-89HO261
NCI-T89-0175C, T89-0175
Last Modified:
6/1/1991
10.
Phase I Pharmacologically Guided Study of Pyrazine Diazohydroxide in Patients with Advanced Cancer (Summary Last Modified 06/91)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
NCI
UCCRC-5961
NCI-T90-0156C, T90-0156
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute